Weiss N, Binder G, Keller C
Medizinische Poliklinik, Klinikum Innenstadt, Ludwig-Maximilians-Universität München, Germany.
Eur J Med Res. 1998 Feb 21;3(1-2):20-4.
Familial hypercholesterolemia (FH) is caused by mutations in the low-density lipoprotein (LDL) receptor gene. We used a multiplex-PCR based single-strand conformation polymorphism analysis to screen the promotor region and all 18 exons of the LDL receptor gene for mutations in patients clinically diagnosed as having FH to identify their particular gene defect. An affected proband was found to be heterozygous for a missense mutation, replacing guanine to adenine at nucleotide 1171 of exon 8 of the gene. This mutation is predicted to cause a substitution of alanine to threonine at codon 370 (A370T). The base exchange abolishes a HaeIII restriction site. PCR of exon 8 followed by restriction enzyme digestion with HaeIII conveniently allowed to screen the whole family and 101 unrelated normocholesterolemic subjects from the same ethnic background for the presence of this mutation. The A307T mutation did not cosegregate with the clinical phenotype of hypercholesterolemia in the affected family. Furthermore the mutation was identified in a heterozygous state in 12 out of 101 and in a homozygous state in 1 out of 101 normocholesterolemic subjects, indicating that this mutation is a frequent genetic variation of the LDL receptor gene in the population examined. Lipid values of probands carrying the wild type LDL receptor allele and the mutation in a heterozygous state did not differ significantly. The proband carrying the mutation on both LDL receptor alleles had high normal cholesterol and LDL cholesterol levels. The A370T mutation represents the third single-amino acid change of the LDL receptor protein reported so far, which, in a heterozygous state, is not associated with the clinical phenotype of familial hypercholesterolemia. The pathophysiologic significance of homozygosity for this mutation remains to be clarified.
家族性高胆固醇血症(FH)由低密度脂蛋白(LDL)受体基因突变引起。我们采用基于多重聚合酶链反应(PCR)的单链构象多态性分析,对临床诊断为FH的患者的LDL受体基因启动子区域和全部18个外显子进行突变筛查,以确定其特定的基因缺陷。发现一名受累先证者为错义突变的杂合子,该基因第8外显子核苷酸1171处的鸟嘌呤被腺嘌呤取代。预计该突变会导致密码子370处的丙氨酸被苏氨酸取代(A370T)。碱基交换消除了一个HaeIII限制性酶切位点。对第8外显子进行PCR,然后用HaeIII进行酶切,便于对整个家族以及来自相同种族背景的101名血脂正常的无关个体进行该突变的筛查。在受累家族中,A307T突变与高胆固醇血症的临床表型不共分离。此外,在101名血脂正常的个体中,12名个体为该突变的杂合子,1名个体为纯合子,这表明该突变在所检测人群中是LDL受体基因常见的遗传变异。携带野生型LDL受体等位基因和该突变杂合子的先证者的血脂值无显著差异。两个LDL受体等位基因均携带该突变的先证者的胆固醇和LDL胆固醇水平略高于正常。A370T突变是迄今为止报道的LDL受体蛋白的第三次单氨基酸改变,杂合状态下与家族性高胆固醇血症的临床表型无关。该突变纯合子的病理生理意义仍有待阐明。